About Eurand
Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products using our proprietary drug formulation technologies. A publicly traded company (NASDAQ: EURX), Eurand has operating units in the United States and Europe.
Eurand is dedicated to the continued development and commercialization of breakthrough products intended to satisfy patients’ needs. Research efforts are focused on the development of treatment options with enhanced efficacy, superior safety, and convenient dosing. Eurand has a number of products in development for the company and its co-development partners that are commercialized worldwide. Through continued investment in R&D, Eurand has a very exciting pipeline of products in various stages of development that, upon approval for the market, will continue to bring benefits to patients and their caregivers.
Eurand’s business strategy is focused in the following areas:
Sales and Marketing of Specialty Healthcare Products in the U.S.
Eurand is focused on the research, development and commercialization in the United States of products for use in the treatment of Cystic Fibrosis and gastrointestinal-related diseases.
Development & Licensing of Products and Technologies
Eurand is a leading global pharmaceutical technology company and is focused on the co-development of partnered products and the out-licensing of Eurand’s products worldwide.
Eurand has one of the broadest ranges of drug delivery platforms in the industry, including:
- Bioavailability Enhancement
- Customized Drug Release
- Taste Masking / Orally Disintegrating Tablets (ODT)
Eurand uses these technologies to develop and expand the company’s internal pipeline and to partner with pharmaceutical and biopharmaceutical companies to develop their products.
